Thyrocare Technologies reported Q2 profit up ~81% YoY at ₹47.8 crore.
Its revenue rose ~22.1% to ~₹216.5 crore.
The board declared an interim dividend of ₹7 per share.
It also approved a bonus issue in ratio 2:1 (2 shares fo
r 1 held).
Upbeat earnings could draw renewed interest in healthcare / diagnostics names.
The combination of bonus + dividend is a strong gesture to shareholders.
But growth must sustain to justify valuations.
Use stop losses to manage volatility in small /
mid cap names.
Peer & sector performance will be a drag / support.
Thyrocare becomes a high-watch specialty name for ne
xt moves.